An open‐label phase 1 trial is evaluating the efficacy and safety of CEA‐targeted CAR T cell therapy in relapsed or refractory CEA+ cancers (NCT04348643) assessing cancers like CRC. Here, CEACAM5 is linked to colorectal carcinoma.